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ABSTRACT
Background: Bipolar disorders (BD) have been accompanied with disturbances in
neuroplasticity. Brain-derived neurotrophic factor (BDNF) plays important role in
neuroplasticity. It plays a vital role in the neurobiology of such disorders. This study
aimed to check BDNF serum levels in euthymic BD type I patients and correlate them
with the clinical manifestations. Methods: Forty-eight Egyptian individuals were
included in this study. They were arranged in three groups: The first one ‘G-A’
included twelve patients diagnosed with bipolar I disorder in manic episode; while the
second ‘G-B’ consisted of twelve patients diagnosed with bipolar I disorder in full
remission, and the third group ‘G-C’ consisted of 24 healthy persons as control
subjects. The cases were diagnosed according to DSM-5 and psychometric analysis.
The BDNF levels were assessed using the technique of quantitative sandwich enzyme
immunoassay. Results: There was no statistical significant difference between the
studied groups as regard demographic characteristics. Serum BDNF levels were lower
in bipolar I patients in manic episode compared with those in euthymic state and also
control subjects. Conclusion: patients with manic episode of bipolar I disorder have
lower serum BDNF levels compared with those with euthymic state and control group.
Keywords: Brain-derived neurotrophic factor, bipolar disorder, manic episode.

INTRODUCTION
DNF regulates the neuronal growth ,
controls intersynaptic activity and supports
the bioactivity of neurons[1].BDNF is known
to be found in in large amount in the cerebral
cortex, hippocampus and many brain sites,
especially those responsible for higher brain
operations including memory and feelings[2].
Changes of Serum BDNF level in the
periphery may be the indicator for its level
alteration in the brain as it passes blood brain
barrier and also many researches in animal
showed that its blood level is highly associated
with its level in the cerebrospinal fluid[3].
Bipolar disorder is a disease which
consist of many aspects including periods of
significant mood swing, dysfunction of
neuropsychological ability, and alteration of
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immunity and biological function[4].Among
causes of worldwide disability, bipolar disorder
is considered one of its main cause and is linked
with high incidence of death in young age as a
result of suicide and associated medical
problems[5].
The exact cause of bipolar disorder up
till now is not explored enough, however many
studies that try to know exact pathophysiology
of bipolar disorder shedded light on role of
genetics and epigenetics in its neurobiology.
recently remodeling of the neuronosynaptic
organization and change in cell growth or
apopotosis have been reported to strongly
correlated with the occurrence of bipolar
disorder, so it can be a result of damage of
neurons (e.g., after long term stress, chronic
increased levels of glucocorticoids, ischemia,
89 | P a g e
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decrease blood glucose level, viral infections,
neurotoxins, etc.)[6].
In a way to recognize the underlying
etiology of bipolar disorder, several researches
examined BDNF serum level in different
episodes of BD[7].
BDNF was first studied to clarify the
aetiopathology of mood disorder. It was a good
option as its level in blood can be a mirror
image of its concentration in brain since it
passes blood brain barrier freely [8].
Alteration of levels of BDNF in blood
of bipolar patients have been reported by
previous studies in manic episode and also
depressive episode but with heterogeneity of
results and lack of standard values of BDNF
level[9,10]
This study was designed to test the
hypothesis that serum BDNF level decrease
during acute manic episode and it could be used
as biomarker to distinguish these patients from
bipolar patients in remission and healthy
control, so the aim of study was To investigate
the serum BDNF levels in patients with bipolar
I disorder during manic, episode in comparison
to also bipolar I patients in euthymic state and
healthy control matched for age, gender and
socioeconomic state.
METHODS
This is a case control research that was
carried in the Zagazig university hospitals at
Psychiatry department in collaboration with
department of Medical Biochemistry. The
research was preceded on 48 individuals
classified as follow: The first one ‘G-A’
included twelve patients diagnosed with bipolar
I disorder in manic episode (manic group);
while the second ‘G-B’ consisted of twelve
patients diagnosed with bipolar I disorder in full
remission (euthymic group), and the third group
‘G-C’ consisted of 24 healthy persons as control
subjects (control group). The sample size was
estimated statistically by professor in public
health department according to the power of
study, which equal to 80%, confidence interval
95%, the BDNF in control equals 0.2±0.07
while in bipolar I patients equals 0.014 ± 0.04.
Recruitment occurred from 8 April 2018
to 31 December 2018 and subjects who met the
following eligibility criteria at enrollment were
invited to participate: 1) male and female
gender were included. 2) Age ranged from 18 to
60 years-old. 3) Patients met the criteria of
DSM-5 for bipolar I disorder, Current or most
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1.

2.

3.

4.

5.

recent episode mania or depressed in full
remission. 4) All participants in the healthy
control group will be matched for age, gender
and social class. We excluded subjects with: 1)
Age below 18 or above 60. 2) History of any
physical or general medical condition. 3)
History or present symptoms of any other
psychiatric disorder. 4) Mental retardation. 5)
Refusal of participation. Approval from zagazig
Faculty of Medicine Institutional Research
Board is obtained and all participants wrote an
informed consent. All subjects were interviewed
by a psychiatrist subjected to:
Collection of demographic data and clinical
information:all subjects have been subjected to
semi-structured
questionnaire
specifically
developed for this study which designed to
collect socio-demographic data as age, sex,
marital state, education, occupation, Family
history and history of presenting illness:
Including age of onset, the periods of current
episode and total illness, count of preceding
episodes, suicidality and violence.
“Structured clinical interview for dsm-iv-tr
axis i disorders (SCID-I)”: To exclude current
psychiatric disorders of Axis I. It is structured
checklist interview that helps by its end to reach
DSM-IV diagnosis as it contains a majority of
psychiatric disorders with its subtypes [11].
“Diagnostic criteria of DSM-5 for bipolar I
disorder”: to establish diagnosis of acute manic
episode and bipolar I in remission according to
the new diagnostic and statistical manual of
mental disorders, 5th Edition (DSM-5) [12]
“Young Mania Rating Scale (YMRS)”: To
assess symptoms of mania and its severity. It is
a highly reliable scale, consists of eleven items
that screen all manic symptoms (some graded
from zero to four and others from zero to eight).
The rating depends mostly on the observation of
the clinician and also on the words of the
patients. This scale takes less than half hour to
end and to consider patient in euthymia, he
should have score lower than twelve[13]
“Hamilton
Depression
Rating
Scale
(HDRS)”: To rate Symptoms’ severity of
depression. It consists of twenty one items. The
scoring based on the first seventeen items that
sum to give the final score while the remaining
items are used to characterize manifestation of
depression rather than the severity of it. This
scale takes from twenty to thirty minutes to be
completed and patient considered euthymic if
he scored less than twelve[14]
90 | P a g e
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6. “Biochemical BDNF Assessment”: to all
participants serum BDNF concentrations were
measured by enzyme-linked immunoassay
(ELISA) quantitatively. In which the protein
which is targeted (antigen) linked by primary
antibodies capture (specific for human BDNF)
which coated to bottom of the well and then the
researcher added secondary detection antibodies
(A sample 3ml of venous blood was withdrawn
under complete aseptic conditions from all
subjects; and then left to clot for 30 min ,
centrifuged and the serum was stored in liquor
at 20° C. Repeated freezing and thawing was
avoided[15]
The work has been carried out in
accordance with The Code of Ethics of the
World Medical Association (Declaration of
Helsinki) for studies involving humans.
Statistical analysis:
- Statistical analysis was done using SPSS
software version twenty five. Data was
presented in tables and figures.
- Quantitative data was showed as mean, median
and range.
- Qualitative data was demonstrated as
frequencies and relative percentages.
- Pearson’s chi square (χ2) test was used to
calculate difference between qualitative
variables.
- One-way ANOVA (F-test) test was used to
calculate difference between quantitative
variables in more than two groups in normally
distributed data.
- Kruskal-Wallis (KW) test was used to calculate
difference between quantitative variables in
more than two groups in not normally
distributed data.
- Mann Whitney test (MW) was used to analyze
continuous data between two groups.
- Spearman’s correlation coefficient (r) was used
to test correlation between BDNF and
continuous variables.
- Receiver operating characteristic (ROC) curves
were plotted for the optimal cut-off values of
serum BDNF. The optimal cut-off values were
defined as the values that allow discrimination
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between case and control groups with highest
sensitivity and specificity.
For all above mentioned statistical tests done,
the threshold of significance is fixed at 5% level
(P-value) and P value of <0.05 indicates
significant results.
RESULTS
[Table 1] showed that there was no statistical
significant difference between the studied
groups as regard demographic characteristics.
In [table 2] there were high statistical
significant differences between the studied
groups as regard serum BDNF levels. Manic
patients had the lowest serum BDNF level with
median (155.7 pg/ml) while in euthymic group
and control it was (164.5 pg/ml and 420.0
pg/ml) respectively.
[Table 3] showed that in manic group there
was statistical significant positive correlation
between age of onset of first manic episode and
serum BDNF level (r = 0.061, P = 0.03),
negative correlation between duration of bipolar
illness and serum BDNF level (r = - 0. 63, P =
0.2) and also negative correlation between
number of previous mood episodes and serum
BDNF level (r = - 0. 59, P = 0.04). There was
no statistical significant correlation between
suicide (MW = 1.5, P = 0.1), violence (MW =
0.6, P = 0.6) or family history (MW = 0.2, P =
0.8) and serum BDNF level.
[Table 4] and [figure 1] showed that, the best
Cutoff point of
serum BDNF level in
distinguishing patients with manic episode from
Healthy controls was (166.3 pg/ ml )
corresponding
with
(100%)
diagnostic
performance accuracy , sensitivity and
specificity with highly significant area under the
curve of (AUC) the ROC curve (p ˂0.001).
In [table 5] and [figure 2], the best Cutoff
point of serum BDNF level in distinguishing
patients with manic episode from patients with
euthymic state of bipolar I disorder was Less
than (160.7 pg/ ml) corresponding with (91.7%)
diagnostic performance accuracy, (100%)
sensitivity and (83.3%) specificity with highly
significant AUC of the ROC curve (p ˂0.001).

91 | P a g e
3

Zagazig University Medical Journal, Vol. 27 [2021], Iss. 1, Art. 31

January. 2021 Volume 27 Issue 1

10.21608/zumj.2019.13540.1251

Table 1. Demographic characteristics of the studied groups.

















Variables
Manic group (n=12) Euthymic group (n=12) Control group (n=24) Test of sig.
Age (years):
29.8 ± 3.2
27.8 ± 7.2
30.0 ± 7.3
f
Mean ± SD
24.0
–
35.0
19.0
–
46.0
21.0
–
46.0
1.0
Range
Gender:
7 (58.3%)
3 (25.0%)
14 (58.3%)
χ2
Males
5 (41.7%)
9 (75.0%)
10 (41.7%)
5.1
Females
Marital status:
5 (41.7%)
5 (41.7%)
10 (41.7%)
χ2
Single
5 (41.7%)
4 (33.3%)
12 (50.05)
9.3
Married
2 (16.7%)
3 (25.05)
0 (0.0%)
Divorced
0 (0.0%)
0 (0.0%)
2 (8.3%)
Widow
Education:
0 (0.0%)
1 (8.3%)
0 (0.0%)
χ2
Illiterate
0 (0.0%)
1 (8.3%)
2 (8.3%)
7.2
Elementary
1 (8.3%)
0 (0.0%)
2 (8.3%)
Preparatory
5 (41.7%)
6 (50.0%)
8 (33.3%)
Secondary
6 (50.0%)
4 (33.3%)
12 (50.0%)
High education
Occupation:
5 (41.7%)
7 (58.3%)
6 (25.0%)
χ2
Working
7 (58.3%)
5 (41.7%)
18 (75.0%)
5.5
Not working

P
0.3

0.1

0.4

0.8

0.1

Table 2. Serum level of brain-derived neurotrophic factor (BDNF) in the studied groups.
BDNF
Mean ± SD
Median
Range

Manic group
155.3 ± 4.1
155.7
149.3 – 160.3

Euthymic group
166.2 ± 5.7
164.5
159.0 – 176.0

Control group
2332.6 ± 3110.9
420.0 *
172.3 – 10226.0

KW

P

52.8

˂0.001
HS

* Significantly higher than other groups
Table 3. Correlation between serum BDNF level and Clinical characteristics of manic group.
Clinical characteristics
Age of onset
Disease duration
Number of previous episodes
Suicide, Median (Range):
Positive, 150.7 (149.7 - 151.6)
Negative, 156.9 (149.3 - 160.3)
Violence, Median (Range):
Positive, 152.7 (149.3 – 159.4)
Negative, 156.0 (149.7 – 160.3)
Family history, Median (Range):
Positive, 155.4 (151.6 – 158.8)
Negative, 157.7 (149.3 – 160.3)

Abd El., et al..
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r
0.61
-0.63
-0.59
MW

P
0.03 (S)
0.2 (S)
0.04 (S)
P

1.5

0.1

0.6

0.6

0.2

0.8
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Table 4.The Diagnostic performance accuracy of serum BDNF level in distinguishing patients with
manic episode from Healthy controls.
Diagnostic performance
Manic group
Cutoff point
Less than 166.3 (pg/ ml)
Sensitivity
100%
Specificity
100%
Positive predictive value
100%
Negative predictive value
100%
Accuracy
100%
Likelihood ratio positive
∞
Likelihood ratio negative
0.00
Area under the curve (AUC)
1.0 (1.0 – 1.0)
P
0.001 (HS)

Figure 1. Receiver operating characteristic (ROC) curve using serum BDNF level to discriminate
manic group patients from healthy controls.
Table 5. The Diagnostic performance accuracy of serum BDNF level in distinguishing patients with
manic episode from patients in euthymic state of bipolar I disorder.
Diagnostic performance
Manic group
Cutoff point
Less than 160.7 (pg/ ml)
Sensitivity
100%
Specificity
83.3%
Positive predictive value
85.7%
Negative predictive value
100%
Accuracy
91.7%
Likelihood ratio positive
6.1
Likelihood ratio negative
0.00
Area under the curve
0.97 (0.9 – 1.0)
P
˂0.001 (HS)
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Figure 2. Receiver operating characteristic (ROC) curve using serum BDNF level to discriminate
patients with manic episode from patients in euthymic state of bipolar I disorder.
DISCUSSION
Demographic characteristics of the study
sample are shown in [table 1] and exhibits that
the patients with bipolar I disorder in manic
episode and euthymic state were not significantly
different with the healthy controls in terms of age,
gender, marital status, education and occupation.
As shown at [table 2] the present study showed
that serum BDNF levels were decreased in
bipolar I disorder patients during manic episode
compared to healthy control subjects which is
statistically significantly (p˂0.001), which are
consistent with previous studies like [16-18] who
demonstrated that levels of serum BDNF were
significantly lowered in bipolar I patients during
manic episode in comparison with healthy
controls . But, in contrary to these studies, [19]
reported that manic patients with bipolar I
disorder exhibit elevated levels of serum BDNF
comparing with healthy controls.
This discrepancy may be due to the various
effect of the different modality of treatment used
to control manic symptoms on serum BDNF as
the patients in study that showed increase BDNF
in manic patients compared with control may be
treated with lithium or valproate or both which
assumed to increase serum BDNF as supported
by [20] who reported that lithium inhibits the
glycogen synthase kinase 3 (GSK-3)
and
valproate inhibits sodium channel function, which
leads to increases cellular levels of BDNF.
In this study manic patients group were
recruited in acute episode and some of them not
took any medications and others were
noncompliant on treatment so the decrease in
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serum BDNF may be owed to biological changes
occurs in mania. This view is supported by study
of [21] who revealed that in the manic episode of
bipolar disorder , there is a marked elevation in
protein kinase C (PKC) (that is a part in the proinflammatory response) mediated signaling,
which is accompanied with BDNF dependent
Ca2+ induction and subsequent decrease of serum
BDNF [21]..
Also, in Table (2) showed statistically
significant difference between manic group and
euthymic group as regard serum BDNF levels
(p˂0.001).Manic group had lower serum BDNF
level than euthymic group as in manic group
serum BDNF level range from (149.3 pg/ml) to
(160.3 pg/ml) with median (155.7 pg/ml) while in
euthymic group it range from (159.0 pg/ml) to
(176.0pg/ml) with median (164.5 pg/ml).
These result in agreement with [22] who
showed significant decrease levels of BDNF in
patients with bipolar disorder ( manic episodes) in
comparison euthymic patients [22].. Also, [23]
reported that BDNF levels are lower during manic
episode of bipolar disorder type I, but that after
treatment for acute mania they are not
significantly different from patient in remission.
This increase of serum BDNF level in bipolar
patients in remission may owe to the effect of
treatment as explained before.
Table (3) showed that in manic group there was
statistical significant positive correlation between
age of onset of first manic episode and serum
BDNF level (r = 0.061, P = 0.03), negative
correlation between duration of bipolar illness
and serum BDNF level (r = - 0. 63, P = 0.2) and
94 | P a g e
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also negative correlation between number of
previous mood episodes and serum BDNF level (r
= - 0. 59, P = 0.04). There was no statistical
significant correlation between suicide (MW =
1.5, P = 0.1), violence (MW = 0.6, P = 0.6) or
family history (MW = 0.2, P = 0.8) and serum
BDNF level.
These findings are consistent with study of [24]
which showed that levels of BDNF decrease with
increase bipolar disorder duration. Also, they
showed that during mania, age and duration of
illness are important factors that have a role in
determination of BDNF levels, and are at least
partially responsible for the discrepancies of
BDNF levels during mania.
This supported by other study that reported that
serum BDNF has hopeful properties that capable
of differentiation between patients had bipolar
disorder less than three years from those with
more than ten years[25].
With increase duration of bipolar illness the
patient was prone more to more mood episode
with more stress with more decrease in serum
BDNF level. The reason might be that the
protective and compensatory mechanisms were
not able to sustain BDNF levels when neuronal
damage were extensive in each acute episode
which may reflect the neurodegeneration of late
stage bipolar disorders. 8.
In contrast to this study is this obtained by
[26]who found significant positive associations
between serum BDNF levels and illness duration,
and manic episodes only in female bipolar
disorder patients. This difference can be
explained by the fact that the patients in Dias et
al. study were not in acute manic episode but in
euthymic state .
In assessment of the diagnostic performance
accuracy of serum BDNF in the current study,
serum BDNF levels demonstrated a high accuracy
of being able to discriminate bipolar I disorder in
manic episode patients from healthy controls with
cutoff point (166.3 pg/ ml ) corresponding with
highly significant area under the curve (AUC) of
the ROC curve (p ˂0.001) as sown in Table (4)
and Figure (1).
Moreover Table (5) and Figure (2) showed
that, the best Cutoff point of serum BDNF level
in distinguishing patients with manic episode
from patients with euthymic state of bipolar I
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disorder was Less than (160.7 pg/ ml)
corresponding
with
(91.7%)
diagnostic
performance accuracy, (100%) sensitivity and
(83.3%) specificity with highly significant AUC
of the ROC curve (p ˂0.001).
These findings are comparable to that of
[24]who found highly favourable characteristics
of serum BDNF with sensitivity 90% and
specificity of 85% elucidate that levels of BDNF
can accurately differentiate between manic
patients from healthy controls.
CONCLUSIONS
By the end of this study, it is found that serum
BDNF level was statistically lowered in manic
episode compared with control group, also serum
BDNF level was statistically higher in patients in
euthymic state compared with manic episode of
bipolar I disorder.The serum BDNF levels
showed high diagnostic performance accuracy to
distinguish bipolar I disorder patients in manic
episode from healthy controls, also from
euthymic state.Studies with long duration, larger
number of patients in different episodes of mood
and early stages of bipolar disorder are necessary
to clarify exact BDNF role in bipolar disorders.
One of the essential limitations of this study is
the small number of studied subjects.One more
limitation was that pharmacological treatments
cannot included in the statistical analysis as most
patients took multiple combinations of different
psychotropic medication and also most of patients
weren’t adherent to treatment. Moreover., due to
the
high likelihood of rapid disease decompensating
that is successfully controlled by chronic use of
medication, stopping drugs to rule out the effect
of psychotropic drugs on serum BDNF
concentration is neither suggested nor ethically
acceptable.
Conflict of Interest: Nothing to declare.
Financial disclosure: Nothing to declare.
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